Prilosec patent ruling
This article was originally published in The Tan Sheet
Executive Summary
Omeprazole generics status quo unchanged by a federal appeals court's Dec. 11 ruling affirming that Schwarz' generic does not infringe AstraZeneca's Prilosec patents, but that ANDAs filed by Andrx, Genpharm and Dr. Reddy's do infringe. Federal Circuit upheld a New York trial court's October 2002 ruling, which led to an agreement by Andrx and Genpharm to relinquish their first-to file exclusivity rights on omeprazole to Schwarz in exchange for a profit-sharing agreement on its Kudco subsidiary's product. Schwarz' position as the sole generic entry ended in August, when "second wave" defendants Mylan and Novartis' Lek division launched at risk with litigation pending in the trial court...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.